P/E ratio for Regeneron Pharmaceuticals (REGN)
P/E ratio as of September 2023 (TTM): 20.7
According to Regeneron Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 20.7119. At the end of 2021 the company had a P/E ratio of 8.26.
P/E ratio history for Regeneron Pharmaceuticals from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 8.26 | -43.98% |
| 2020 | 14.7 | -23.92% |
| 2019 | 19.4 | 17.5% |
| 2018 | 16.5 | -50.5% |
| 2017 | 33.3 | -23.64% |
| 2016 | 43.6 | -50.47% |
| 2015 | 88.1 | -25.67% |
| 2014 | 119 | 86.53% |
| 2013 | 63.6 | 192.43% |
| 2012 | 21.7 | |
| 2010 | -25.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 32.0 | 54.42% | 🇺🇸 USA |
 Novartis NVS | 28.0 | 35.27% | 🇨🇭 Switzerland |
 Amgen AMGN | 18.0 | -13.00% | 🇺🇸 USA |
 Sanofi SNY | 18.5 | -10.83% | 🇫🇷 France |
 Biogen BIIB | 14.0 | -32.51% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -20.3 | -198.16% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.